Remove Access Remove Article Remove Clinical Trials Remove Safety
article thumbnail

Report: Efficacy and safety of medical cannabinoids in children: a systematic review and meta-analysis

Cannabis Law Report

Scientific Reports volume 11 , Article number: 23462 ( 2021 ) Cite this article. Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. Metrics details.

Safety 52
article thumbnail

Article: Cannabis & CBD Pharma NewsNews Does medicinal cannabis actually help Australian patients?

Cannabis Law Report

Access to medicinal cannabis for patients was legalised in Australia in 2016, allowing doctors to request permission to prescribe from the Australian government. This is at least due to the difficulty and cost involved in accessing a legal prescription. Patient access pathways.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Cannabis Helps, Say Over Half of Parkinson’s Patients Who Use It

The Cannigma

This article was originally published on Analytical Cannabis and appears here with permission. . Of these consumers, over half said the drug had a beneficial clinical effect on their condition. Patients can also access CBD products without a prescription through local pharmacies. Still, research is ongoing.

article thumbnail

Harvard Is Launching America’s First Psychedelics Law and Policy Center

SpeedWeed

The Project on Psychedelics Law and Regulation (POPLAR) is a three-year project aiming to “promote safety, innovation, and equity in psychedelics research, commerce, and therapeutics,” the university said in a press release. View original article. Professor of Law at Harvard Law School. “By

Policy 52
article thumbnail

New PTSD study finds cannabis safe, but not as effective as assumed

SpeedWeed

for the production of cannabis used in federally-regulated clinical trials. Early on in the study, criticism over the poor quality and low potency of the NIDA-supplied cannabis prompted Johns Hopkins University to withdraw from the multi-year clinical trials. View Bruce Kennedy’s articles.

article thumbnail

Harvard Law Review: Patents on Psychedelics: The Next Legal Battlefront of Drug Development

Cannabis Law Report

Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. Importantly, control of psychedelics by a small number of companies may stifle innovation and reduce access to these therapies. Trial of Psilocybin Versus Escitalopram for Depression , 384 NEW ENG.

article thumbnail

Here’s what you need to know about cannabis research

The Cannigma

There’s no doubt that the amount of information that is available about cannabis is at an all-time high – in 2020 alone, over 3,500 scientific articles were published on the topic. This is because these types of studies control the most variables to ensure that the results that come out of the trial are as reliable as possible.